Egle Pavyde appointed as VP of Business Development

by Bilyana Petrova | Sep 15, 2025 | News

We are thrilled to announce that Egle Pavyde has joined APICES CRO as Vice President of Business Development. With over 10 years of experience in the clinical trials field, she brings the expertise needed to help APICES’ clients...

Facing Clinical Research Challenges? Here’s How to Succeed.

by Bilyana Petrova | Sep 10, 2025 | News

Biotechs operate under enormous pressure: they need to deliver solid scientific results, meet tight deadlines, manage limited resources, and navigate an increasingly demanding regulatory environment in our clinical research. With no room for error, success...

APICES acknowledged for its role in the GGCP 081/21 Study

by Bilyana Petrova | Sep 3, 2025 | News

We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the GGCP 081/21 study, an Observational retrospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Clinical and...

APICES acknowledged for its role in LOADH Study 

by Bilyana Petrova | Aug 28, 2025 | News

We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the LOADH study, an Observational prospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Cancer Research and Clinical Oncology...

APICES Adapts to the ICH E6(R3) Revolution in Clinical Research

by Bilyana Petrova | Aug 19, 2025 | News

The recent release of the ICH E6(R3) guidelines represents a pivotal moment for global clinical research. These updated standards aim to modernize the concept of Good Clinical Practice (GCP), ensuring it remains relevant in an environment of...

APICES at ASCO 2025: Shaping Breakthroughs in Oncology

by Bilyana Petrova | Jul 1, 2025 | News

The ASCO 2025 congress in Chicago, Illinois united the global Oncology community to discuss the latest breakthroughs in cancer research. APICES, as a CRO with 16 years of experience in Oncology clinical trials, we were honored to be part...